Embark on a New Journey
  • Entering rapid development of Stage 2.0  
  • Orelabrutinib for the treatment of r/r marginal zone lymphoma (MZL) approved in China
  • Promising data of orelabrutinib for the treatment of multiple sclerosis
  • InnoCare and ArriVent achieve clinical development collaboration
Soar to New Heights for a Brighter Future
  • InnoCare is listed on the Shanghai Stock Exchange STAR Market (688428.SH)
  • Positive Phase IIa results of orelabrutinib for the treatment of systemic lupus erythematosus
  • The first prescription of tafasitamab in combination with lenalidomide in Bo‘ao and approved for marketing in Hong Kong
  • Orelabrutinib approved for marketing in Singapore
Beyond Dreams, Setting New Milestones
  • The first prescription of orelabrutinib to benefit patients with lymphoma in China
  • Orelabrutinib granted Breakthrough Therapy designation by the U.S. FDA
  • Orelabrutinib included in China’s national reimbursement drug list (NRDL)InnoCare receives the rights to develop and exclusively commercialize tafasitamab in Greater China
Create Exciting Chapters Together
  • InnoCare successfully listed on the Hong Kong Stock Exchange (9969.HK)
  • Orelabrutinib approved for marketing in China
  • Establishment of a dedicated commercial team Completed Phase I of InnoCare Guangzhou Site
Forge Ahead Towards a Promising Future
  • Submission of NDA for orelabrutinib in China
Journey to Pursue Dreams
  • Orelabrutinib showing efficacy in patients with lymphoma in clinical trials
Dreams Take Off
  • Initiated Phase 1 clinical trial of orelabrutinib
Setting Sail
  • Established Beijing and Nanjing Research and Development centers
The Beginning
  • Dr. Jasmine Cui and Dr. Yigong Shi co-founded InnoCare